Recent findings showing that effects of gemtuzumab ozogamicin correlated with higher surface expression levels of CD33 [39] suggest that interventions that may increase surface expression of CD33 would be attractive for CD33- targeted immunotherapeutic strategies in AML. Here, CD33 is linked to acute myeloid leukemia.